October 24, 2016
Toronto, ON—Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced the appointment of José Iglesias, MD as Vice President, Medical and Clinical Affairs with responsibility for providing scientific support for late stage development and commercialization of the company's growing pipeline. Dr. Iglesias has significant global experience in pharmaceutical research and drug development, and commercialization over the past 25 years.
"As we continue work toward bringing our biosimiliars to market and expand our portfolio of innovative therapeutics, Dr. Iglesias' R&D expertise and experience in leveraging commercial opportunities will be exceedingly valuable to the company," says Steve Lydeamore, President, Apobiologix.
Dr. Iglesias previously held global senior leadership positions in clinical development at Bionomics, Abraxis BioScience, Celgene, Amgen Canada, and Eli Lilly, where he applied his deep expertise in hemato-oncology therapeutics towards successful drug development initiatives. Most recently, Dr. Iglesias held the position of Chief Medical Officer at Biothera Pharmaceuticals, where he was responsible for the development of its clinical immuno- oncology pipeline.
A trained medical physician, Dr. Iglesias is the author of more than 60 publications and has served on the grant review board for the Canadian Institutes of Health Research (Medical Research Council of Canada) within the University-Industry Programme. He is an active member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO).
2400 North Commerce Parkway,
Weston, Florida 33326